Efficiency and safety of belimumab in the treatment of lupus nephritis in Chinese adults:a meta-analysis
OBJECTIVE To systematically evaluate the real-world effectiveness and safety of belimumab in the treatment of lupus nephritis(LN)in Chinese adult patients.METHODS Retrieved from PubMed,Embase,Web of Science,Cochrane Library,Wanfang data,CNKI,VIP and CBM,real-world studies on belimumab in the treatment of LN in Chinese adult patients were collected from the inception to July 7th,2023.Two reviewers independently screened the literature,extracted data,and assessed the quality of the included studies.Meta-analysis was then performed using RevMan 5.3 software.RESULTS A total of 10 real-world studies were included,involving 253 Chinese adult patients with LN.The results of the meta-analysis demonstrated that the complete renal response rate,partial renal response rate,and the incidence of adverse reaction rate in Chinese adult patients with LN treated with belimumab were 61%(95%CI was 46%-76%,P＜0.000 01),23%(95%CI was 2%-44%,P=0.03),and 30%(95%CI was 16%-43%,P＜0.000 01),respectively.Belimumab could reduce the 24-hour urinary protein(MD=-1.71,95%CI was-3.02--0.40,P=0.01),urine protein-creatinine ratio(MD=-1.76,95%CI was-2.06--1.46,P＜0.000 01),the systemic lupus erythematosus disease activity index(MD=-8.63,95%CI was-12.12--5.13,P＜0.000 01),and glucocorticoids dosage(MD=-18.65,95%CI was-31.82--5.48,P=0.006).In addition,it could elevate the levels of complement C3(MD=0.19,95%CI was 0.08-0.30,P=0.000 6)and complement C4(MD=0.06,95%CI was 0.02-0.09,P=0.001).However,belimumab could not improve the levels of serum creatinine and estimated glomerular filtration rate(P＞0.05).CONCLUSIONS Belimumab has good efficacy and safety in Chinese adult patients with LN.
lupus nephritisbelimumabreal-world studiesChinaadult patientdisease activity index
万方数据
